NRX Pharmaceuticals is a company that develops innovative drugs for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its most advanced product, ZYESAMI, has recently completed a Phase IIb/III clinical study for COVID-19 related respiratory failure. The company also focuses on developing oral therapeutics for bipolar depression targeting acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.